DYN250117C30000
- 1.75
- 0.000.00%
Dyne Therapeutics Newsroom
Dyne Therapeutics: Positive Phase 1/2 Trial Results for DYNE-101 Lead to Buy Rating and Overweight Stock Recommendation
Dyne Therapeutics Is Maintained at Buy by Chardan Capital
Dyne Therapeutics Price Target Maintained With a $55.00/Share by HC Wainwright & Co.
Dyne Therapeutics Analyst Ratings
RBC Capital Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $45
H.C. Wainwright Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $55
Oppenheimer Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $55
Oppenheimer Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $55
Piper Sandler Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $53
Dyne Therapeutics Analyst Ratings
Baird Initiates Dyne Therapeutics(DYN.US) With Buy Rating, Announces Target Price $46
Oppenheimer Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $55
Piper Sandler Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $53
Piper Sandler Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $53
Dyne Therapeutics Analyst Ratings
RBC Capital Initiates Dyne Therapeutics(DYN.US) With Buy Rating, Announces Target Price $45
Dyne Therapeutics Is Maintained at Buy by Chardan Capital
Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $52
Oppenheimer Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $55
Oppenheimer Sticks to Their Buy Rating for Dyne Therapeutics (DYN)